Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate Ointment for Anal HSIL
NCT06206564Phase 2Recruiting
- Sponsor
- Frantz Viral Therapeutics
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in anal squamous intraepithelial lesion (ASIL) comparing Artesunate Ointment with Placebo Ointment (2 arms). Primary endpoint: Complete and partial histopathologic response at 18 weeks. Started Jan 2024; status: recruiting.
02
Drugs
artesunate
03
Conditions
anal squamous intraepithelial lesion (ASIL)
Beyond the preview
Go deeper on NCT06206564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06206564.